Copyright Reports & Markets. All rights reserved.

Global and China Monoclonal antibodies (mAbs) Biosimilars Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Erythropoietin (EPO)
    • 1.2.3 Human Growth Hormone (HGH)
    • 1.2.4 Granulocyte- Colony Stimulating Factor (G-CSF)
    • 1.2.5 Monoclonal Antibody (mAb)
    • 1.2.6 Insulin
    • 1.2.7 Interferon (IFN)
    • 1.2.8 Others
  • 1.3 Market by Application
    • 1.3.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Application: 2020 VS 2026
    • 1.3.2 Anti-Cancer
    • 1.3.3 Anti-Inflammatory/Autoimmune
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Perspective (2015-2026)
  • 2.2 Global Monoclonal antibodies (mAbs) Biosimilars Growth Trends by Regions
    • 2.2.1 Monoclonal antibodies (mAbs) Biosimilars Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Monoclonal antibodies (mAbs) Biosimilars Historic Market Share by Regions (2015-2020)
    • 2.2.3 Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Market Size
    • 3.1.1 Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Revenue (2015-2020)
    • 3.1.2 Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Players (2015-2020)
  • 3.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Monoclonal antibodies (mAbs) Biosimilars Revenue
  • 3.4 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio
    • 3.4.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Monoclonal antibodies (mAbs) Biosimilars Revenue in 2019
  • 3.5 Key Players Monoclonal antibodies (mAbs) Biosimilars Area Served
  • 3.6 Key Players Monoclonal antibodies (mAbs) Biosimilars Product Solution and Service
  • 3.7 Date of Enter into Monoclonal antibodies (mAbs) Biosimilars Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Type (2015-2026)

  • 4.1 Global Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Type (2015-2020)
  • 4.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Type (2021-2026)

5 Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Application (2015-2026)

  • 5.1 Global Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Application (2015-2020)
  • 5.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2026)
  • 6.2 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
  • 6.3 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
  • 6.4 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2026)
  • 7.2 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
  • 7.3 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
  • 7.4 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2026)
  • 8.2 China Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
  • 8.3 China Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
  • 8.4 China Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2026)
  • 9.2 Japan Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
  • 9.3 Japan Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
  • 9.4 Japan Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size (2015-2026)
  • 10.2 Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 Biocon
    • 11.1.1 Biocon Company Details
    • 11.1.2 Biocon Business Overview
    • 11.1.3 Biocon Monoclonal antibodies (mAbs) Biosimilars Introduction
    • 11.1.4 Biocon Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020))
    • 11.1.5 Biocon Recent Development
  • 11.2 Celltrion
    • 11.2.1 Celltrion Company Details
    • 11.2.2 Celltrion Business Overview
    • 11.2.3 Celltrion Monoclonal antibodies (mAbs) Biosimilars Introduction
    • 11.2.4 Celltrion Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
    • 11.2.5 Celltrion Recent Development
  • 11.3 Dr. Reddy's Laboratories
    • 11.3.1 Dr. Reddy's Laboratories Company Details
    • 11.3.2 Dr. Reddy's Laboratories Business Overview
    • 11.3.3 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Introduction
    • 11.3.4 Dr. Reddy's Laboratories Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
    • 11.3.5 Dr. Reddy's Laboratories Recent Development
  • 11.4 Hospira
    • 11.4.1 Hospira Company Details
    • 11.4.2 Hospira Business Overview
    • 11.4.3 Hospira Monoclonal antibodies (mAbs) Biosimilars Introduction
    • 11.4.4 Hospira Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
    • 11.4.5 Hospira Recent Development
  • 11.5 3SBio
    • 11.5.1 3SBio Company Details
    • 11.5.2 3SBio Business Overview
    • 11.5.3 3SBio Monoclonal antibodies (mAbs) Biosimilars Introduction
    • 11.5.4 3SBio Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
    • 11.5.5 3SBio Recent Development
  • 11.6 Accord Healthcare
    • 11.6.1 Accord Healthcare Company Details
    • 11.6.2 Accord Healthcare Business Overview
    • 11.6.3 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Introduction
    • 11.6.4 Accord Healthcare Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
    • 11.6.5 Accord Healthcare Recent Development
  • 11.7 AET Biotech
    • 11.7.1 AET Biotech Company Details
    • 11.7.2 AET Biotech Business Overview
    • 11.7.3 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Introduction
    • 11.7.4 AET Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
    • 11.7.5 AET Biotech Recent Development
  • 11.8 Allergan
    • 11.8.1 Allergan Company Details
    • 11.8.2 Allergan Business Overview
    • 11.8.3 Allergan Monoclonal antibodies (mAbs) Biosimilars Introduction
    • 11.8.4 Allergan Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
    • 11.8.5 Allergan Recent Development
  • 11.9 Amega Biotech
    • 11.9.1 Amega Biotech Company Details
    • 11.9.2 Amega Biotech Business Overview
    • 11.9.3 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Introduction
    • 11.9.4 Amega Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
    • 11.9.5 Amega Biotech Recent Development
  • 11.10 Others
    • 11.10.1 Others Company Details
    • 11.10.2 Others Business Overview
    • 11.10.3 Others Monoclonal antibodies (mAbs) Biosimilars Introduction
    • 11.10.4 Others Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2015-2020)
    • 11.10.5 Others Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Monoclonal antibodies (mAbs) Biosimilars Scope and Market Size
    Monoclonal antibodies (mAbs) Biosimilars market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Monoclonal antibodies (mAbs) Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Erythropoietin (EPO)
    Human Growth Hormone (HGH)
    Granulocyte- Colony Stimulating Factor (G-CSF)
    Monoclonal Antibody (mAb)
    Insulin
    Interferon (IFN)
    Others

    Market segment by Application, split into
    Anti-Cancer
    Anti-Inflammatory/Autoimmune

    Based on regional and country-level analysis, the Monoclonal antibodies (mAbs) Biosimilars market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Monoclonal antibodies (mAbs) Biosimilars market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Biocon
    Celltrion
    Dr. Reddy's Laboratories
    Hospira
    3SBio
    Accord Healthcare
    AET Biotech
    Allergan
    Amega Biotech
    Others

    Buy now